Home › Melanoma › Minnesota › Rochester
Melanoma clinical trials in Rochester, MN
16 studies for Melanoma are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
- Mayo Clinic in Rochester, Rochester
Pan-tumor MRD Study
RecruitingObservational study
- Mayo Clinic, Rochester
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RecruitingPhase 2
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- Mayo Clinic (Rochester), Rochester
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- Mayo Clinic - Rochester, Rochester
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Recruiting
- Mayo Clinic in Rochester, Rochester
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RecruitingObservational study
- Mayo Clinic in Rochester, Rochester
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
RecruitingPhase 1/2
- Mayo Clinic Rochester, Rochester
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
- Mayo Clinic - PPDS, Rochester
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- Mayo Clinic Rochester, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecruitingObservational study
- Mayo Clinic, Rochester
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RecruitingPhase 3
- Mayo Clinic Minnesota, Rochester
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
RecruitingPhase 3
- Mayo Clinic, Rochester
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RecruitingPhase 1/2
- Mayo Clinic in Minnesota, Rochester
About Melanoma
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
More about Melanoma on MedlinePlus
Melanoma trials in other cities
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN32 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Salt Lake City, UT21 studies
- Atlanta, GA21 studies
- Columbus, OH21 studies
- St. Louis, MO20 studies
Other studies in Rochester
- Breast Cancer42 studies
- Non-Small Cell Lung Cancer38 studies
- Cancer (all types)31 studies
- Metastatic Cancer30 studies
- Colorectal Cancer29 studies
- Ovarian Cancer29 studies
- Multiple Myeloma23 studies
- Pancreatic Cancer23 studies
- Heart Failure22 studies
- Prostate Cancer22 studies
- Lung Cancer20 studies
- Endometrial Cancer19 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.